奥希替尼序贯治疗表皮生长因子受体突变阳性非小细胞肺癌患者：观察性 GioTag 研究的更新分析。
Sequential afatinib and osimertinib in patients with mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study.
机构信息
Department of Respiratory & Critical Care Medicine, & Ludwig Boltzmann Institute of COPD & Respiratory Epidemiology, Otto Wagner Hospital, Sanatoriumstrasse 2, Vienna 1140, Austria.
Thoracic Medical Oncology, Istituto Nazionale Tumori, 'Fondazione G Pascale'-IRCCS, 80131 Napoli, Italy.
出版信息
Future Oncol. 2019 Sep;15(25):2905-2914. doi: 10.2217/fon-2019-0346. Epub 2019 Aug 2.
Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. NCT03370770.
在 GioTag 研究的真实世界环境中，接受序贯阿法替尼/奥希替尼治疗的 突变阳性（Del19、L858R）非小细胞肺癌患者的总生存期（OS）和更新的治疗失败时间（TTF）分析。这些患者在一线阿法替尼治疗后出现 T790M 阳性疾病，并接受奥希替尼治疗（n=203）。主要结局为 TTF。OS 分析为探索性分析。总体中位 OS 为 41.3 个月（95%CI：36.8-46.3），Del19 阳性肿瘤患者为 45.7 个月（95%CI：45.3-51.5）（n=149）；2 年生存率分别为 80%和 82%。阿法替尼和奥希替尼的更新中位 TTF 为 28.1 个月（95%CI：26.8-30.3）。序贯阿法替尼/奥希替尼治疗与 T790M 阳性非小细胞肺癌患者的令人鼓舞的 OS/TTF 相关，尤其是 Del19 阳性肿瘤患者。NCT03370770。
Zotero 插件